Uncategorized

Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy

Published

1 week ago

on

In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version